Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of
the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as
an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate
Alzheimer's disease.